Literature DB >> 32907879

Proteolytic cleavage of Podocin by Matriptase exacerbates podocyte injury.

Shota Ozawa1,2, Masaya Matsubayashi3, Hitoki Nanaura3, Motoko Yanagita1,4,5, Kiyoshi Mori1,6, Katsuhiko Asanuma1,7, Nobuyuki Kajiwara8, Kazuyuki Hayashi8, Hiroshi Ohashi9, Masato Kasahara10, Hideki Yokoi4, Hiroaki Kataoka11, Eiichiro Mori12, Takahiko Nakagawa13,3.   

Abstract

Podocyte injury is a critical step toward the progression of renal disease and is often associated with a loss of slit diaphragm proteins, including Podocin. Although there is a possibility that the extracellular domain of these slit diaphragm proteins can be a target for a pathological proteolysis, the precise mechanism driving the phenomenon remains unknown. Here we show that Matriptase, a membrane-anchored protein, was activated at podocytes in CKD patients and mice, whereas Matriptase inhibitors slowed the progression of mouse kidney disease. The mechanism could be accounted for by an imbalance favoring Matriptase over its cognate inhibitor, hepatocyte growth factor activator inhibitor type 1 (HAI-1), because conditional depletion of HAI-1 in podocytes accelerated podocyte injury in mouse model. Matriptase was capable of cleaving Podocin, but such a reaction was blocked by either HAI-1 or dominant-negative Matriptase. Furthermore, the N terminus of Podocin, as a consequence of Matriptase cleavage of Podocin, translocated to nucleoli, suggesting that the N terminus of Podocin might be involved in the process of podocyte injury. Given these observations, we propose that the proteolytic cleavage of Podocin by Matriptase could potentially cause podocyte injury and that targeting Matriptase could be a novel therapeutic strategy for CKD patients.
© 2020 Ozawa et al.

Entities:  

Keywords:  Matriptase; Podocin; chronic kidney disease; diabetic nephropathy; hepatocyte growth factor activator inhibitor type 1; kidney; podocyte; protease; protease inhibitor

Year:  2020        PMID: 32907879      PMCID: PMC7681011          DOI: 10.1074/jbc.RA120.013721

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1.

Authors:  Jessica J Harris; Hugh J McCarthy; Lan Ni; Matthew Wherlock; HeeGyung Kang; Jack F Wetzels; Gavin I Welsh; Moin A Saleem
Journal:  J Pathol       Date:  2013-02-22       Impact factor: 7.996

2.  Design and synthesis of potent, selective inhibitors of matriptase.

Authors:  Eloïc Colombo; Antoine Désilets; Dominic Duchêne; Félix Chagnon; Rafael Najmanovich; Richard Leduc; Eric Marsault
Journal:  ACS Med Chem Lett       Date:  2012-04-11       Impact factor: 4.345

3.  Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity.

Authors:  Makiko Kawaguchi; Naoki Takeda; Shinri Hoshiko; Kenji Yorita; Takashi Baba; Akira Sawaguchi; Yuriko Nezu; Tsutomu Yoshikawa; Tsuyoshi Fukushima; Hiroaki Kataoka
Journal:  Am J Pathol       Date:  2011-08-12       Impact factor: 4.307

4.  Podocyte-specific expression of tamoxifen-inducible Cre recombinase in mice.

Authors:  Hideki Yokoi; Masato Kasahara; Masashi Mukoyama; Kiyoshi Mori; Koichiro Kuwahara; Junji Fujikura; Yuji Arai; Yoko Saito; Yoshihisa Ogawa; Takashige Kuwabara; Akira Sugawara; Kazuwa Nakao
Journal:  Nephrol Dial Transplant       Date:  2010-02-11       Impact factor: 5.992

5.  Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.

Authors:  M Murakawa; T Okamura; T Shibuya; M Harada; T Otsuka; Y Niho
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

Review 6.  Serine proteases, inhibitors and receptors in renal fibrosis.

Authors:  Allison A Eddy
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

7.  Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.

Authors:  Olivier Bardou; Awen Menou; Charlène François; Jan Willem Duitman; Jan H von der Thüsen; Raphaël Borie; Katiuchia Uzzun Sales; Kathrin Mutze; Yves Castier; Edouard Sage; Ligong Liu; Thomas H Bugge; David P Fairlie; Mélanie Königshoff; Bruno Crestani; Keren S Borensztajn
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

8.  Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus.

Authors:  I Ebihara; T Nakamura; N Shimada; H Koide
Journal:  Am J Kidney Dis       Date:  1998-10       Impact factor: 8.860

9.  A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.

Authors:  Mohammad Saleem; Vaqar Mustafa Adhami; Weixiong Zhong; B Jack Longley; Chen-Yong Lin; Robert B Dickson; Shannon Reagan-Shaw; David F Jarrard; Hasan Mukhtar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

10.  Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Authors:  Katsuyuki Tanabe; Miguel A Lanaspa; Wataru Kitagawa; Christopher J Rivard; Makoto Miyazaki; Jelena Klawitter; George F Schreiner; Moin A Saleem; Peter W Mathieson; Hirofumi Makino; Richard J Johnson; Takahiko Nakagawa
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15
View more
  1 in total

1.  Mechanistic insights into the use of rhubarb in diabetic kidney disease treatment using network pharmacology.

Authors:  Yingyuan Gao; Zheng Nan
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.